EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 8304351
• 负责人: Selina M Luger
• 金额: $ 37.65万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8304351
• 关键词: Abramson Cancer Center at the University of Pennsylvania; Applications Grants; Area; Beds; Cancer Center; Cancer Family; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Colon Carcinoma; Commit; Communities; Comprehensive Cancer Center; Conduct Clinical Trials; Data Quality; Development; Diffusion; Disorder by Site; Drug Industry; Eastern Cooperative Oncology Group; Eligibility Determination; Ensure; Environment; Equipment; Faculty; Financial Support; Floor; Funding; Grant; Hand; Hematology; Hospitals; Housing; Human Resources; Individual; Inpatients; Institutes; Institution; Intensive Care Units; Knowledge; Laboratories; Lead; Leadership; Left; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Medical Oncology; Medicine; Modality; Modeling; Monitor; National Cancer Institute; Nurses; Operative Surgical Procedures; Outpatients; Patient Care; Patients; Pennsylvania; Physicians; Play; Presbyterian Church; Principal Investigator; Program Development; Protocols documentation; Protons; Radiation Oncology; Radiation therapy; Radiology Specialty; Radiosurgery; Relative (related person); Research; Research Institute; Research Personnel; Resource Sharing; Resources; Review Committee; Role; Site; Societies; Technology; Training; United States; United States National Institutes of Health; Universities; University Hospitals; anticancer research; cancer research center director; cancer therapy; cost; data management; drug development; falls; human subject; malignant breast neoplasm; multidisciplinary; multimodality; nondrug therapy; oncology; patient oriented; patient population; population based; programs; protocol development; square foot

DESCRIPTION (provided by applicant): This application is being submitted to continue the University of Pennsylvania's role as a main institution in the Eastern Cooperative Oncology Group beyond its 37 years of continuous particpation. The overarching objectives are to continue to serve as a scientific and administrative resource for the Group, to enter patients onto ECOG protocols, and to coordinate and support a large affiliate network. In the latter role, this application will support the diffusion of knowledge of clinical trials, assist in the proper conduct of clinical trials, and make these trials accessible to the broadest possible population of patients with cancer. Although the University of Pennsylvania has had an outstanding track record in all aspects of cooperative group activities, including accrual, administrative and scientific input and data quality, the specific aims of the proposal for the next six years are to: 1. continue to enhance accrual in all disease site and modalities, beyong our current particpation, particularly in breast and lung cancers. 2. increase physician, nurse, and data management participation in Group activities, including protocol development. 3. attract new affilaites through the Abramson Cancer Center network, allowing for enhanced availability for clinical trials participation in the larger community The relevance of this project to the ultimate cure of cancer is self-evident. Cooperative groups are the main force outside of the pharmaceutical industry dedicated to the definitve tesing of new treatments, studying not just new drug development but also non-drug treatment, such as radiation therapy and surgery, for which there would be nooter funding. These cooperative group activities, and the specific involvement of the University of Pennsylvania, represent the chief way in which the ultimate model of multimodal, collaborative patient care can be performed. The main ECOG grant describes in detail the very specific way in which clinical trials have led to RELEVANCE: Malignancies remain an enormous burden for individuals in the United States and for society as a whole. Without public support of clinical trials, both by financial support as well as participation in clinical trials, progress will not be made. If left in private hands, large areas of cancer treatment will go unexplored, denying patients the possibility of progress.

描述（由申请人提供）：正在提交申请，以继续宾夕法尼亚大学作为东部合作肿瘤学集团的主要机构的角色，超过其连续37年的参与度。总体目标是继续作为该小组的科学和行政资源，将患者输入ECOG协议，并协调和支持大型会员网络。在后者的角色中，该应用将支持临床试验知识的扩散，有助于适当进行临床试验，并使这些试验可用于最广泛的癌症患者人群。尽管宾夕法尼亚大学在合作团体活动的各个方面都有出色的往绩，包括应计，行政和科学意见和数据质量，但未来六年的提案的具体目的是：1。继续增强所有疾病现场的应计值，在所有疾病现场，我们目前的肉欲，尤其是母乳和Lung Cancers。 2。增加医师，护士和数据管理参与包括协议开发在内的小组活动。 3.通过艾布拉姆森癌症中心网络吸引新的会员，从而增强了临床试验参与较大社区的可用性，该项目与癌症的最终治疗的相关性是不言而喻的。合作群体是专门用于确定新疗法的制药行业之外的主要力量，不仅研究新药开发，而且还研究非药物治疗，例如放射治疗和手术，为此提供了Nooter资助。这些合作小组活动以及宾夕法尼亚大学的特定参与代表了可以进行多模式，协作患者护理的最终模型的主要方式。主要的ECOG赠款详细描述了临床试验导致的非常具体的方式 相关性：在美国和整个社会中，恶性肿瘤仍然是一个巨大的负担。没有公众对临床试验的支持，无论是通过财务支持还是参与临床试验，都不会取得进展。如果私下手中，大部分癌症治疗将无法探索，否认患者的进展可能性。